This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NexMed Files Investigational New Drug Application With FDA For Cancer Drug Candidate

NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT ® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.

PrevOnco (the anti-ulcer compound, lansoprazole, approved under the name Prevacid® and marketed in the U.S. by Takeda Pharmaceuticals North America, Inc.) had been under development by FasTrack Pharmaceuticals, Inc. for the treatment of solid tumors, in particular, for the treatment of HCC. FasTrack received orphan Drug status for PrevOnco from the FDA in August 2008. In vitro and in vivo pre-clinical data generated to date has demonstrated the ability of lansoprazole to inhibit tumor cell growth and enhance survival in mouse models of cancer alone, and in combination with doxorubicin.

NexMed recently acquired PrevOnco from San Diego-based FasTrack Pharmaceuticals, which was spun out of Bio-Quant in October 2009; NexMed acquired Bio-Quant in December 2009. As an upfront payment, NexMed paid approximately $205,000 in the form of the cancellation of indebtedness owed by FasTrack to Bio-Quant. In addition, FasTrack and NexMed will share equally in any future revenues, including payments received from potential licensing partners, after first deducting NexMed’s future development expenses, including a 15% premium.

NexMed’s prospective, open label, single-arm, multicenter Phase II trial will assess the safety and efficacy of lansoprazole and doxorubicin in patients with advanced unresectable HCC at up to 10 study sites throughout the U.S. The primary objective of the study is to assess the response rate to doxorubicin and lansoprazole. Subjects will be treated with oral lansoprazole 90mg twice daily and intravenous (IV) doxorubicin 60 mg/m 2 administered every 21 days. Subjects will continue to receive IV doxorubicin plus lansoprazole, if tolerated, up to a maximum of six consecutive cycles of doxorubicin, as long as there is no evidence of progressive disease. A total of between 15 and 70 subjects are expected to be enrolled in the study for a period of up to 12 months in the absence of disease progression or intolerance. Total study duration is anticipated to be one to three years, depending on the rate of enrollment and number of patients enrolled.

Commenting on today’s news, Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, “Acquiring the rights to PrevOnco represents NexMed’s entrance into oncology and adds an important product candidate to our pipeline. With a solid safety profile, generated from over 15 years of human use of lansoprazol for the treatment of ulcers, and early indications of anti-cancer activity observed in pre-clinical studies, we believe that PrevOnco is a strong candidate for development with NexMed’s proprietary NexACT drug delivery technology as a second generation compound. Our recent filing of the IND with the FDA is a major milestone for NexMed, and we look forward to initiation of the Phase II trial.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,982.59 +22.02 0.13%
S&P 500 1,978.91 +0.57 0.03%
NASDAQ 4,444.9090 -4.6550 -0.10%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs